Ligand validation:6CVU

CTN: 4-AMINO-1-BETA-D-RIBOFURANOSYL-2(1H)-PYRIMIDINONE

CTN is a Ligand Of Interest in 6CVU designated by the Author

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
6CVU_CTN_B_303	56%	32%	0.173	0.945	1.38	1.3	2	3	0	0	100%	0.92
6CVU_CTN_A_303	52%	23%	0.147	0.905	1.57	1.6	3	4	0	0	100%	0.83
6CVU_CTN_D_303	48%	34%	0.153	0.897	1.33	1.26	1	2	0	0	100%	0.94
6CVU_CTN_C_303	19%	34%	0.263	0.862	1.34	1.25	2	2	0	0	100%	0.86
6NN0_CTN_D_303	16%	31%	0.259	0.825	1.47	1.27	3	2	1	0	100%	0.77
9GN4_CTN_A_201	97%	45%	0.059	0.973	0.73	1.37	-	3	0	0	100%	1
4JS1_CTN_A_510	95%	33%	0.059	0.962	1.45	1.22	1	1	0	0	100%	1
5LOK_CTN_A_303	93%	13%	0.095	0.99	1.44	2.53	3	5	1	0	100%	0.39
3IVE_CTN_A_603	93%	48%	0.088	0.982	0.86	1.15	-	1	1	0	100%	1
6YA4_CTN_C_401	93%	34%	0.092	0.986	1.24	1.38	2	3	0	0	100%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.